| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
45,480,000 |
| Market
Cap: |
110.97(M) |
| Last
Volume: |
155,617 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.7085 - $2.3 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Ocuphire Pharma is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Co.'s primary product candidate, Nyxol® Eye Drops, is a once-daily eye drop formulation of phentolamine mesylate designed to reduce pupil diameter and improve visual acuity. Co.'s second product candidate, APX3330, is a twice-a-day oral tablet designed to target multiple pathways relevant to retinal and choroidal (the vascular layer of the eye) diseases such as diabetic retinopathy and diabetic macular edema which, if left untreated, can result in permanent visual acuity loss and eventual blindness.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
100,000 |
255,500 |
| Total Buy Value |
$0 |
$0 |
$97,600 |
$297,693 |
| Total People Bought |
0 |
0 |
1 |
5 |
| Total Buy Transactions |
0 |
0 |
1 |
9 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2025-09-11 |
2025-06-10 |
2024-12-10 |
2023-12-11 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Foundation Fighting Blindness, Inc. |
See Remarks |
– • – |
2025-12-09 |
4 |
S |
$2.15 |
$8,600,000 |
D/D |
(4,000,000) |
5,492,171 |
|
- |
|
| Magrath George |
Chief Executive Officer |
• • – |
2025-11-01 |
4 |
D |
$2.30 |
$69,805 |
D/D |
(30,350) |
1,291,654 |
|
- |
|
| Yerxa Benjamin R |
President |
• • – |
2025-10-22 |
4 |
D |
$1.95 |
$46,400 |
D/D |
(23,795) |
319,005 |
|
- |
|
| Gagnon Robert E. |
Chief Financial Officer |
• • – |
2025-09-10 |
4 |
A |
$0.00 |
$0 |
D/D |
200,000 |
200,000 |
|
- |
|
| Gallagher Cam |
|
• • – |
2025-08-25 |
4 |
A |
$1.15 |
$1,000,000 |
D/D |
869,565 |
1,810,430 |
|
- |
|
| Ainsworth Sean |
|
• • – |
2025-08-25 |
4 |
A |
$1.15 |
$99,999 |
D/D |
86,956 |
254,818 |
|
- |
|
| Foundation Fighting Blindness, Inc. |
See Remarks |
– • • |
2025-05-05 |
4 |
A |
$0.00 |
$0 |
D/D |
6,927,419 |
9,492,171 |
|
- |
|
| Gallagher Cam |
|
• • – |
2025-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
79,504 |
940,865 |
|
- |
|
| Bennett Jean |
|
• • – |
2025-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
79,504 |
213,525 |
|
- |
|
| Rodgers Richard J |
|
• • – |
2025-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
79,504 |
318,655 |
|
- |
|
| Ainsworth Sean |
|
• • – |
2025-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
79,504 |
167,862 |
|
- |
|
| Graves Adrienne L |
|
• • – |
2025-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
79,504 |
79,504 |
|
- |
|
| Benton Susan |
|
• • – |
2025-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
79,504 |
219,527 |
|
- |
|
| Manuso James S J |
|
• • – |
2025-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
79,504 |
261,763 |
|
- |
|
| Schachle Joseph K |
Chief Operating Officer |
• • – |
2025-03-13 |
4 |
A |
$0.00 |
$0 |
D/D |
52,500 |
54,500 |
|
- |
|
| Hoffmann Bernhard |
SVP of Corp. Dev. |
• • – |
2025-03-13 |
4 |
A |
$0.00 |
$0 |
D/D |
29,500 |
185,446 |
|
- |
|
| Zaremba Rabourn Amy |
SVP of Finance |
• • – |
2025-03-13 |
4 |
A |
$0.00 |
$0 |
D/D |
39,500 |
113,968 |
|
- |
|
| Magrath George |
Chief Executive Officer |
• • – |
2025-03-13 |
4 |
A |
$0.00 |
$0 |
D/D |
330,697 |
929,847 |
|
- |
|
| Jayagopal Ashwath |
Chief Scientific & Dev. Ofc. |
• • – |
2025-03-13 |
4 |
A |
$0.00 |
$0 |
D/D |
52,500 |
125,807 |
|
- |
|
| Jhaveri Nirav S. |
Chief Financial Officer |
• • – |
2025-03-13 |
4 |
A |
$0.00 |
$0 |
D/D |
52,500 |
194,293 |
|
- |
|
| Jayagopal Ashwath |
Chief Scientific & Dev. Ofc. |
• • – |
2025-02-13 |
4 |
D |
$1.15 |
$5,972 |
D/D |
(5,193) |
73,307 |
|
- |
|
| Jhaveri Nirav S. |
Chief Financial Officer |
• • – |
2025-02-13 |
4 |
D |
$1.15 |
$9,438 |
D/D |
(8,207) |
141,793 |
|
- |
|
| Hoffmann Bernhard |
SVP of Corp. Dev. |
• • – |
2025-02-04 |
4 |
D |
$1.14 |
$7,696 |
D/D |
(6,751) |
155,946 |
|
- |
|
| Zaremba Rabourn Amy |
SVP of Finance |
• • – |
2025-02-04 |
4 |
D |
$1.14 |
$9,337 |
D/D |
(8,190) |
74,468 |
|
- |
|
| Manuso James S J |
|
• • – |
2025-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
50,222 |
182,259 |
|
- |
|
128 Records found
|
|
Page 1 of 6 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.06 (2.4%) 
